Evicue

Follow the literature without the chase.

[Evicue @evicueapp]

Have you tried turning Evicue notifications on? Fair if you haven't. Most apps abuse that permission. Ours are silent by design, and you can tailor them to your schedule. Worth turning on.

[Evicue @evicueapp]

Aleniglipron (once-daily oral small-molecule GLP-1)
ACCESS phase 2b in obesity/overweight:
~12% weight loss at 36 weeks (high dose) with 86% hitting ≥5% loss.
Credible oral alternative signal. Still early but very promising.

[Evicue @evicueapp]

🧵 Keeping track of next-wave incretins! Four major trials published in just days across obesity, MASLD, and T2D. Different endpoints so no head-to-head rankings but the metabolic pipeline is absolutely on fire 🔥#ObesityMedicine #GItwitter

[Evicue @evicueapp]

Retatrutide (weekly injection, triple GIP + GLP-1 + glucagon)
TRANSCEND-T2D-1 phase 3 in early type 2 diabetes:
HbA1c drops up to -1.94% and weight loss up to 15.3% at 40 weeks.
Broadest metabolic mechanism in the pipeline right now.

[Evicue @evicueapp]

Unprecedented moment for progressive metastatic pancreatic cancer.
#GItwitter #ASCO26

https://t.co/0p9NdYhYwM

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

A powerful moment at #ASCO26
Dr Brian Wolpin (@DanaFarberNews) received a standing ovation during a field shifting plenary.
Overall survival data from @RevMedicines RASolute 302 trial - a true highlight from #ASCO2026
#PancreaticCancer

[Evicue @evicueapp]

🚨 Big HBV breakthrough in @NEJM. For a disease where “success” has always meant lifelong suppression, bepirovirsen just put functional cure on the table:

1 in 5 patients reached functional cure at week 72 vs 0% on placebo, and the result was replicated across two trials.

This genuinely changes what patients and clinicians can hope for.

https://t.co/2bgbRVRlb9

#GItwitter #HBV #LiverTwitter

[Evicue @evicueapp]

Strong ‘hit hard 💪, then hold steady’ signal in UC! 📈
Upadacitinib + vedolizumab induction more than doubled week-8 endoscopic remission (37.5% vs 15.1%) vs vedolizumab alone in a randomized trial. Stopped early for efficacy.
Promising finite combo induction strategy.

[Evicue @evicueapp]

🚨 New RCT 🚨 BARI-STEP (@NatureMedicine) In patients with poor weight loss post-bariatric surgery, semaglutide 2.4 mg led to ~18% weight loss at 68 weeks vs. placebo. Powerful reminder that obesity care is a continuum, not a single event. #GITwitter #ObesityMedicine
https://t.co/kLVFLTY2YI

[Evicue @evicueapp]

Chronic HDV now has its first FDA-approved therapy! The landmark NEJM RCT established the efficacy signal and the J Hepatol follow-up adds the longer term data: responses can deepen on therapy, but stopping is selective. #GITwitter #HDV

[Evicue @evicueapp]

Now in Evicue Hallmarks: a @Gut_BMJ RCT that puts evidence behind a common overnight ERCP decision. In mild-to-moderate acute cholangitis, ERCP <24h was not superior to 24-48h for mortality or organ failure. Timely drainage, without overcalling urgency. #GITwitter @ASGEendoscopy

[Ash Almomani, MD @AlmomaniMD]

Evicue is probably the most useful app I’ve downloaded in 2026 (in addition o OpenEvidence) to stay on top of evidence-based GI. Ya’ll should try it 🔥

#GItwitter #IBDtwitter

[Evicue @evicueapp]

@Bnmxtra4 @AlmomaniMD We are currently working on the playstore version, stay tuned!

[Evicue @evicueapp]

What's new in Evicue this spring:

Hallmarks is its own tab now. Trials and guidelines that actually shape practice, with their own filters and refresh.

Collections to organize papers into your own folders.

Reverse filters. Invert any filter to exclude in one tap.

Journal impact factor.

Tap abbreviations in a study to see the definition inline.

Download Evicue. Free.

#GItwitter #MedEd #FOAMed

[Evicue @evicueapp]

LIR!C at 10 years (Lancet GH 2026). Early ileocecal resection beat infliximab on therapy free remission, similar overall clinical remission. The surgery vs biologic debate is back open for IBD teaching.

Download Evicue. Hallmarks for the trials worth teaching, Latest for what's new.

https://t.co/pQYcFjkitO

#GItwitter #IBD #MedEd #FOAMed